SEC-sourced researchBeta
NNNN
Anbio Biotechnology
Company comparison ↗
Data passport
- CIK
- 0001982708
- Exchange
- Nasdaq
- Business activity
- — · SIC 2835
- Financial inputs
- 6/6
- Filing date
- Apr 7, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 6,711,990.0000 | Apr 7, 2026 |
| December 2024 | 8,185,146.0000 | Apr 7, 2026 |
| December 2025 | 8,646,844.0000 | Apr 7, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 8,646,844.0000 | 6,403,463.0000 | -6,739,075.0000 | 30,242,859.0000 | 87,836.0000 | Apr 7, 2026 |
| December 2024 | 8,185,146.0000 | 2,372,842.0000 | 2,080,387.0000 | 18,921,784.0000 | 1,730,234.0000 | Apr 7, 2026 |
| December 2023 | 6,711,990.0000 | 2,253,709.0000 | 898,367.0000 | — | — | Apr 7, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenues | $8.65M | December 2025 | Apr 7, 2026 | 20-F |
| Previous period revenueRevenues | $8.19M | December 2024 | Apr 7, 2026 | 20-F |
| Net incomeNetIncomeLoss | $6.4M | December 2025 | Apr 7, 2026 | 20-F |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$6.74M | December 2025 | Apr 7, 2026 | 20-F |
| Total assetsAssets | $30.24M | December 2025 | Apr 7, 2026 | 20-F |
| Total liabilitiesLiabilities | $87.84K | December 2025 | Apr 7, 2026 | 20-F |